AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
ORLANDO, FLA. -- Sentinel node biopsies are appropriate for a much larger pool of breast cancer patients than previously thought, and testing biopsied tissue for a newly identified breast cancer biomarker appears to substantially reduce the false-negative rate.
Those conclusions emerged from two studies reported at a meeting of the Department of Defense Breast Cancer Research Program.
Currently, older women and those who have advanced breast disease, multiple tumors, or past breast surgery are not considered to be good candidates for the sentinel node biopsy procedure, because these patients exhibit a high rate of false-negative results.
But Dr. Lorraine Tafra said that her study of 1,236 women who underwent breast cancer biopsy showed that surgeon inexperience with the procedure and a low number of sentinel nodes obtained were the factors most associated with high false-negative rates.
The data showed no association between a false-negative reading and patient age, tumor type or location, multiple vs. single cancer sites in the breast, or the use of preoperative chemotherapy.